What BPC-157 Is
BPC-157 is a 15-amino-acid synthetic pentadecapeptide: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The sequence corresponds to residues 62–76 of human gastric juice protein BPC (Body Protection Compound).
It is not a hormone, receptor ligand by primary mechanism, or growth factor. It is a research compound with documented interactions across multiple signaling systems.
The NO System Connection
The most extensively studied mechanism for BPC-157 involves the nitric oxide (NO) system. Research in multiple GI tissue models shows BPC-157 modulates NO production — specifically through interactions with the L-arginine-NO pathway.
The significance: NO is a central regulator of GI mucosal blood flow, smooth muscle tone, and barrier function. BPC-157's NO interactions directly map to its documented mucosal protection effects in animal models.
VEGF Receptor Upregulation
Secondary research streams document BPC-157's upregulation of VEGF receptor 2 (VEGFR2). VEGF signaling drives angiogenesis — new blood vessel formation — which is critical to tissue repair processes.
In wound healing models, BPC-157 treatment accelerated both angiogenesis markers and epithelial repair timing. The VEGFR2 interaction provides a mechanistic explanation for observations that were initially characterized purely at the tissue level.
The Dopaminergic and Serotonergic Dimensions
BPC-157 research has also documented interactions with dopaminergic and serotonergic systems — particularly relevant given that the gut contains approximately 90% of the body's serotonin. These interactions may partially explain BPC-157's documented effects in stress-ulcer models.
Why It Pairs with GLP Research
GLP-1R agonists reduce gastric motility and caloric throughput. In extended GLP-based research protocols, the reduction in mucosal turnover stimulation from reduced food intake creates a relevant context for GI mucosal integrity studies. BPC-157's documented mucosal protection effects in this context make it a logical research companion.
The pairing addresses a specific research question: can GI mucosal integrity be maintained during reduced-intake GLP protocols? BPC-157 is the most studied compound for this research application.
The Publication Count
40+ peer-reviewed publications specifically addressing BPC-157 GI effects since the mid-1990s. The compound is not obscure in the research literature — it has a more substantial published base than most peptides at comparable price points.